SXTP
60 Degrees Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.92
−1.16%Year over year
Reported trailing growth
- Revenue
- +68.0%
- EBITDA
- -4.1%
- EBIT
- -11.7%
- EPS
- +81.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +33.2%
- EBITDA
- -0.1%
- EPS
- +49.4%
Three-year CAGR
- Revenue
- +65.2%
- EBITDA
- +7.7%
- EBIT
- +20.1%
- Net income
- +7.3%
- EPS
- +84.2%
- Free cash flow
- -21.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026